Bringing a drug product to market in the U.S. means entering a process where early decisions shape everything that follows. The regulatory pathway you choose affects the studies you need to conduct, the timing of FDA interactions, and the options available later if plans change. Many sponsors, particularly smaller or emerging companies, enter the process with limited familiarity of FDA regulatory requirements and the steps needed to initiate a development program. Even for teams with some prior experience, each product introduces its own set of variables.
This is why FDA experience matters so much when selecting a regulatory strategy consulting partner. Sponsors need more than a general understanding of regulations. They need guidance from a team that has worked through FDA submissions and managed agency questions under tight timelines.
Regulatory Experience Goes Beyond Theory
Guidance documents provide an essential foundation, but navigating the FDA review process requires more than understanding what the regulations say. The challenge lies in the evaluation and formulation of the response to meet FDA’s expectations during the review process. Details that appear straightforward on paper can raise new questions once a submission reaches FDA reviewers, and the way those questions are addressed can have a ripple effect for every aspect of your program. Because of this, practical experience working through real submissions and agency feedback is often just as important as familiarity with the guidance itself.
Experienced regulatory strategy consulting partners have already encountered similar regulatory questions in prior submissions and understand how those issues were resolved during FDA review. They understand how to frame submissions clearly, what level of detail FDA reviewers expect in different sections, and how to respond to subsequent information requests. This perspective allows them to guide sponsors with lessons learned from real FDA interactions and outcomes. Experienced partners also recognize that regulatory strategy connects closely with technical decisions across formulation, quality, and ongoing lifecycle management. Because of that perspective, these teams approach regulatory planning as part of a broader development strategy, giving sponsors an advantage from day one.
Commonly Missed Regulatory Challenges
Sponsors starting the regulatory submission process for the first time often focus on major milestones such as INDs, NDAs, or other filings. However, the more difficult challenges tend to appear in the operational details surrounding those milestones.
For example, a sponsor pursuing an orphan drug designation for a new indication or dosage form may initially assume the process is straightforward once eligibility criteria are identified. In practice, the submission often requires additional supporting data for the scientific rationale, documentation of disease prevalence, or other evidence requested during FDA review. Teams that have previously worked through these types of interactions are typically better prepared to anticipate those questions and provide a more complete request or assemble the necessary information quickly when requested.
Experienced partners help sponsors prepare for situations including:
- Early definition of the appropriate regulatory pathway: Selecting the appropriate pathway for approval influences study design, data requirements, and the overall development timeline; each option carries different expectations around clinical data and supporting documentation
- Solution: An experienced partner evaluates the product, existing data, and intended indication to identify the most appropriate path; this early clarity helps ensure that formulation work, analytical development, and clinical planning align with the eventual submission strategy
- Meeting the level of detail required for FDA submissions: Many first-time sponsors underestimate the volume of information required in regulatory submissions; beyond scientific data, the FDA expects highly structured documentation that clearly supports every aspect of the application:
- Solution: Experienced regulatory teams understand the formatting, technical writing, and documentation standards required for FDA submissions; they help ensure that data, analyses, and supporting materials are presented in a way that allows reviewers to quickly understand the program and evaluate the submission
- Responding to FDA information requests during review: During the review process, the FDA frequently issues requests for additional information related to submitted data; these requests can arrive with short response windows, sometimes within 24-48 hours, particularly at critical points in the review cycle:
- Solution: An experienced partner anticipates the types of questions that commonly arise; when requests arrive, they can quickly interpret the agency’s question, coordinate the necessary technical input, and assemble a clear response within the required time frame
- Connecting regulatory strategy with technical development decisions: Regulatory planning does not exist in isolation; decisions around formulation, manufacturing processes, analytical methods, and specifications all influence what must ultimately be submitted to the FDA:
- Solution: Experienced teams evaluate these technical elements alongside regulatory expectations to ensure that development work supports the eventual submission; this alignment reduces the risk of late-stage adjustments or additional studies that can delay the submission and/or review of the application.
- Planning for product changes across the lifecycle: Drug products often evolve after initial approval through formulation adjustments, manufacturing changes, or new indications; depending on the scope and potential impact of the change, the FDA requires different types of regulatory submissions to report or obtain approval for those updates:
- Solution: Experienced regulatory advisors help determine whether a change can be reported in an annual report for minor updates, submitted as a CBE supplement for moderate changes, or filed as a prior approval supplement when FDA review is required before implementation; addressing these considerations early allows sponsors to maintain compliance while supporting long-term product availability.
How to Find the Right Regulatory Partner
Choosing a regulatory strategy consulting partner should involve more than confirming familiarity with FDA guidance. When evaluating potential partners, it helps to focus on indicators that show practical experience and the ability to guide programs through real regulatory decisions.
Key factors to look for include:
- Demonstrated experience with FDA submissions such as INDs, NDAs, ANDAs, and 505(b)(2) applications
- Direct involvement in FDA meetings, correspondence, and response preparation
- Understanding of how regulatory strategy connects with quality, formulation development, and lifecycle management
- Experience preparing structured submissions and managing the regulatory submission process
- A proactive approach that anticipates FDA expectations and potential review questions
A Partner Built on Real FDA Experience
Navigating the FDA submissions process requires a clear strategy, careful planning, and the ability to respond effectively as questions arise during development and review. Kiel Laboratories supports sponsors throughout this journey with regulatory strategy consulting grounded in hands-on experience across the drug development lifecycle. With decades of pharmaceutical R&D expertise and a track record that includes multiple NDA approvals, the Kiel team helps sponsors define the right regulatory pathway, prepare well-structured submissions, and manage FDA interactions with confidence.
If you are preparing to start the U.S. regulatory process, connect with us to discuss your next steps.